CN107075583A - 一种用于预测对采用egfr抑制剂治疗的响应性的方法 - Google Patents

一种用于预测对采用egfr抑制剂治疗的响应性的方法 Download PDF

Info

Publication number
CN107075583A
CN107075583A CN201580051832.9A CN201580051832A CN107075583A CN 107075583 A CN107075583 A CN 107075583A CN 201580051832 A CN201580051832 A CN 201580051832A CN 107075583 A CN107075583 A CN 107075583A
Authority
CN
China
Prior art keywords
leu
glu
gly
ser
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580051832.9A
Other languages
English (en)
Chinese (zh)
Inventor
R·蒂埃博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ying Tegaigen Co
Original Assignee
Ying Tegaigen Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ying Tegaigen Co filed Critical Ying Tegaigen Co
Publication of CN107075583A publication Critical patent/CN107075583A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580051832.9A 2014-09-26 2015-09-25 一种用于预测对采用egfr抑制剂治疗的响应性的方法 Pending CN107075583A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306490.5 2014-09-26
EP14306490.5A EP3000895A1 (en) 2014-09-26 2014-09-26 A method for predicting responsiveness to a treatment with an EGFR inhibitor
PCT/EP2015/072095 WO2016046365A1 (en) 2014-09-26 2015-09-25 A method for predicting responsiveness to a treatment with an egfr inhibitor

Publications (1)

Publication Number Publication Date
CN107075583A true CN107075583A (zh) 2017-08-18

Family

ID=51663116

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580051832.9A Pending CN107075583A (zh) 2014-09-26 2015-09-25 一种用于预测对采用egfr抑制剂治疗的响应性的方法

Country Status (10)

Country Link
US (1) US20170298442A1 (enExample)
EP (2) EP3000895A1 (enExample)
JP (1) JP2017529852A (enExample)
KR (1) KR20170086469A (enExample)
CN (1) CN107075583A (enExample)
AU (1) AU2015323744A1 (enExample)
BR (1) BR112017005421A2 (enExample)
CA (1) CA2961434A1 (enExample)
MX (1) MX2017003832A (enExample)
WO (1) WO2016046365A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108034727A (zh) * 2018-01-18 2018-05-15 四川大学华西医院 检测MicroRNA-31-5p表达水平的试剂的用途
CN119303090A (zh) * 2024-10-15 2025-01-14 中国医学科学院北京协和医院 miR-210-3p和/或miR-31-5p在薄型子宫内膜中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2976577C (en) 2015-02-11 2024-11-19 Univ Aarhus MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
WO2016134727A1 (en) * 2015-02-27 2016-09-01 Exiqon A/S A microrna-based method for assessing the prognosis of a prostate cancer patient
KR102480430B1 (ko) * 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459638A (zh) * 2009-06-19 2012-05-16 默克专利有限公司 用于测定抗egfr抗体在癌症治疗中的功效的生物标记和方法
WO2013076282A1 (en) * 2011-11-25 2013-05-30 Integragen A method for predicting responsiveness to a treatment with an egfr inhibitor
CN104046679A (zh) * 2013-03-11 2014-09-17 戴勇 原发性IgA肾病肾脏组织差异表达miRNA的分析方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
US20120095030A1 (en) 2009-04-17 2012-04-19 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
US9598734B2 (en) 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459638A (zh) * 2009-06-19 2012-05-16 默克专利有限公司 用于测定抗egfr抗体在癌症治疗中的功效的生物标记和方法
WO2013076282A1 (en) * 2011-11-25 2013-05-30 Integragen A method for predicting responsiveness to a treatment with an egfr inhibitor
CN104046679A (zh) * 2013-03-11 2014-09-17 戴勇 原发性IgA肾病肾脏组织差异表达miRNA的分析方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LUI WO等: "登录号：MIMAT0000089", 《MIRBASE》 *
MOSAKHANI N等: "MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF", 《CANCER GENETICS》 *
NOSHO K等: "Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway", 《CARCINOGENESIS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108034727A (zh) * 2018-01-18 2018-05-15 四川大学华西医院 检测MicroRNA-31-5p表达水平的试剂的用途
CN119303090A (zh) * 2024-10-15 2025-01-14 中国医学科学院北京协和医院 miR-210-3p和/或miR-31-5p在薄型子宫内膜中的应用

Also Published As

Publication number Publication date
AU2015323744A1 (en) 2017-04-27
CA2961434A1 (en) 2016-03-31
JP2017529852A (ja) 2017-10-12
EP3198028A1 (en) 2017-08-02
US20170298442A1 (en) 2017-10-19
MX2017003832A (es) 2018-02-23
BR112017005421A2 (pt) 2017-12-12
WO2016046365A1 (en) 2016-03-31
EP3000895A1 (en) 2016-03-30
KR20170086469A (ko) 2017-07-26
EP3198028B1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
JP6342329B2 (ja) Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法
CA2567293C (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
EP3198028B1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
US20160376661A1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
WO2010101916A1 (en) Methods for predicting cancer response to egfr inhibitors
US20150344961A1 (en) Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
JP5967699B2 (ja) 遺伝子発現解析による大腸がんの病型分類に基づく抗癌剤応答性及び予後の予測方法
AU2014213541B2 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
JP2014221065A (ja) ２つの遺伝子の発現の観察による乳癌患者の予後診断
AU2011265464A1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818